Kore Private Wealth LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 6.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,064 shares of the medical research company’s stock after purchasing an additional 122 shares during the period. Kore Private Wealth LLC’s holdings in Amgen were worth $503,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of AMGN. Regency Capital Management Inc. DE bought a new stake in shares of Amgen during the first quarter worth $27,000. Maverick Capital Ltd. bought a new stake in shares of Amgen during the first quarter worth $27,000. Elmwood Wealth Management Inc. bought a new stake in shares of Amgen during the first quarter worth $31,000. Wolverine Asset Management LLC increased its position in shares of Amgen by 1,587.5% during the first quarter. Wolverine Asset Management LLC now owns 135 shares of the medical research company’s stock worth $33,000 after acquiring an additional 127 shares in the last quarter. Finally, KB Financial Partners LLC bought a new stake in shares of Amgen during the first quarter worth $35,000. 74.73% of the stock is owned by institutional investors.
Several brokerages have recently issued reports on AMGN. Zacks Investment Research raised shares of Amgen from a “sell” rating to a “hold” rating and set a $255.00 price objective for the company in a research report on Tuesday, June 29th. Mizuho initiated coverage on shares of Amgen in a report on Friday, September 10th. They set a “hold” rating and a $222.00 target price for the company. William Blair restated a “hold” rating on shares of Amgen in a report on Friday, September 17th. Daiwa Capital Markets cut shares of Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 target price for the company. in a report on Thursday, September 23rd. Finally, Morgan Stanley reduced their target price on shares of Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $244.58.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Monday, August 2nd. The medical research company reported $4.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.09 by $0.29. The company had revenue of $6.53 billion for the quarter, compared to analyst estimates of $6.43 billion. Amgen had a net margin of 22.55% and a return on equity of 99.85%. Analysts predict that Amgen Inc. will post 16.41 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 8th. Investors of record on Tuesday, August 17th were given a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date was Monday, August 16th. Amgen’s dividend payout ratio is 42.41%.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
See Also: How is a Moving Average Calculated?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.